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Abstract			 More	so	than	ever,	Multiple	Drug	Resistant	(MDR)	bacteria	are	on	the	rise	due	to	overuse	of	antibiotics	along	with	natural	selection	for	adaptations	that	enhance	drug-resistant	properties.		One	particular	bacterial	family,	Enterobacteriaceae,	has	been	problematic,	exhibiting	several	bacterial	members	that	have	developed	a	precipitous	resistance	to	modern	antibiotics	and	are	also	primary	causative	agents	of	nosocomial,	or	hospital	acquired,	infections.		Citrobacter	
freundii	(CF)	and	Enterobacter	cloacae	(ECL)	are	two	species	of	the	Enterobacteriaceae	family	causing	significant	medical	concern	due	to	their	role	in	producing	numerous	opportunistic	infections	such	as	bacteremia,	lower	respiratory	tract	infections,	urinary	tract	infections,	and	endocarditis.		Adding	to	the	difficulty	of	this	situation	is	the	ability	of	bacteria	to	produce	biofilms.		These	biofilms	are	communities	of	bacteria	that	exhibit	increased	resistance	to	antibiotic	treatment	and	eradication.		Previous	work	in	the	laboratory	of	Dr.	Fox	at	ETSU	has	identified	an	uncharacterized	product	secreted	by	Klebsiella	pneumoniae	(KP),	another	member	of	the	Enterobacteriaceae	family,	which	appears	to	have	inhibitory	effects	toward	CF	and	ECL.		The	current	study	was	designed	to	characterize	the	effects	this	secreted	product	has	on	CF	and	ECL	biofilms.	Through	a	high	throughput	microtiter	plate	assay,	the	effects	of	this	secreted	product	were	examined	on	CF	and	ECL	phases	of	biofilm	attachment	and	maturation.	Based	on	our	findings,	we	have	concluded	that	this	secreted	product	can	be	categorized	as	a	possible	bacteriostatic	agent	against	biofilm	cell	density,	biofilm	mass,	and	cell	viability	for	both	biofilm	
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phases	of	attachment	and	maturation.	These	results	demonstrate	the	potential	for	future	antimicrobial	applications	of	this	product	for	CF	or	ECL	infected	patients.	
Introduction	
Bacterial	Biofilms		 Microorganisms,	much	like	humans,	are	subjected	to	the	mechanisms	of	evolution,	such	as	natural	selection.		As	such,	over	time,	there	have	been	many	diverse	and	unique	adaptations	developed	among	the	microbial	community.		One	such	way	that	bacteria	has	adapted	to	survive	when	conditions	are	less	than	favorable	is	to	mass	together	and	form	a	slimy	film	on	a	wide	variety	of	different	surfaces.		We	call	this	collaborative	phenomenon	biofilm	production.		We	can	define	a	biofilm	as	an	assemblage	of	microbial	cells	that	is	irreversibly	associated	(cannot	be	removed	by	gentle	rinsing)	with	a	surface	and	enclosed	in	a	polymeric	matrix	[1].		Structurally,	a	biofilm	consists	of	numerous	subunits,	referred	to	as	microcolonies.		These	microcolonies	reside	within	a	matrix	of	extracellular	polymeric	substances	(EPS)	with	a	close	proximity	to	each	other.		This,	in	turn,	provides	the	bacteria	with	an	ideal	environment	for	the	creation	of	nutrient	gradients,	gene	exchange,	and	quorum	sensing	activities	[1].		Biofilms	are	amorphous	and	dynamic	complexes	that	can	also	provide	a	community	of	bacteria	with	adaptive	resistance	to	antibiotics	[2].		This	aspect	is	especially	important	due	to	the	worrisome	possibility	that	standard	antibiotics	that	would	typically	inhibit	or	kill	bacteria	in	their	planktonic,	free-swimming	state	fail	to	have	the	same	effect	once	a	biofilm	is	produced	[3,4].		Also,	when	compared	to	free-swimming	bacteria,	
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biofilms	are	much	better	adapted	to	withstand	adverse	environmental	conditions	such	as	nutrient	deprivation,	pH	changes,	oxygen	radicals,	and	even	biocides	[5].		These	adaptive	benefits	are	only	possible	due	to	communities	of	bacteria	joining	together	to	form	coordinated	and	cooperative	groups	that,	some	say,	appear	analogous	to	multicellular	organisms	[6].		The	developed	tolerance	to	antibiotics	alone	makes	it	easy	to	see	the	evolutionary	benefits	of	biofilm	production.		The	communal	setting	of	a	biofilm	illustrates	the	capability	of	bacteria	to	function	cooperatively	and	altruistically	for	their	survival.		The	results	of	this	cooperation	prove	more	efficacious	for	bacteria’s	prosperity	than	simply	existing	in	a	planktonic	form.		As	such,	these	bacterial	slime	layers	are	now	everywhere.		Biofilms	have	become	ubiquitous	in	natural,	industrial,	and	most	worryingly,	clinical	environments	[7].		It	is	now	accepted	that,	between	this	ubiquitous	nature	of	biofilms	and	estimates	that	approximately	90%	of	bacteria	exist	in	biofilms,	living	in	groups	is	critical	for	a	bacteria’s	ecology	and	evolution	[5,6].		The	general	competition	among	bacteria,	even	of	the	same	species,	can	often	result	in	a	“kill	or	be	killed”	methodology.			However,	in	biofilms,	it	is	observed	that	some	bacteria	within	the	biofilms	decrease	their	own	reproductive	output	in	order	to	increase	the	fitness	of	other	cells.		This	can	thereby	benefit	the	biofilm	community	as	a	whole	rather	than	just	an	individual	organism	[6].	Bacteria	are	able	to	produce	biofilms	and	subsequently	work	together	as	a	microbial	community	due	to	a	secretion-detection	mechanism	called	quorum	sensing	(QS).		The	process	of	QS	provides	a	mechanism	for	self-organization	and	regulation	of	microbial	cells.		This	involves	an	environmental	sensing	system	that	
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allows	bacteria	to	monitor	and	respond	to	their	own	population	densities	[3].		Via	the	production	of	diffusible	organic	signaling	molecules,	known	as	auto-inducers,	bacteria	are	able	to	communicate	with	each	other	at	high	enough	population	densities	to	result	in	a	change	of	gene	expression	[2,3].		Once	the	QS	mediating	signaling	is	achieved,	the	microbial	community	can	begin	the	process	of	biofilm	production.		At	present,	processes	governing	biofilm	formation	that	have	been	identified	include:	1)	the	pre-conditioning	of	the	adhesion	surface	either	by	macromolecules	present	in	the	bulk	liquid	or	intentionally	coated	on	the	surface;	2)	Transport	of	planktonic	cells	from	the	bulk	liquid	to	the	surface;	3)	Adsorption	of	cells	at	the	surface;	4)	Desorption	of	reversibly	adsorbed	cells;	5)	Irreversible	adsorption	of	bacterial	cells	at	a	surface;	6)	Production	of	cell–cell	signaling	molecules;	7)	Transport	of	substrates	to	and	within	the	biofilm;	8)	Substrate	metabolism	by	the	biofilm-bound	cells	and	transport	of	products	out	of	the	biofilm;	and	finally	9)	Biofilm	removal	by	detachment	or	sloughing	[3].		Simplified,	the	process	can	be	condensed	to	4	main	steps:	preparation,	attachment,	maturation,	and	dispersion.		Depending	on	the	bacteria,	there	are	numerous	alterations	or	additions	that	can	be	made	with	each	step	as	well	as	multiple	mechanisms	that	can	aid	the	bacteria	in	achieving	their	optimal	conditions	for	biofilm	production.		For	example,	some	bacteria	have	pili	or	other	extracellular	filamentous	appendages	that	aid	in	attachment	[3]	while	others	may	rely	on	the	assistance	of	extracellular	DNA	or	lipids	to	do	the	same	[5].			It	is	worth	revisiting	that	all	of	the	processes	mentioned	above,	from	attachment	onward,	are	occurring	embedded	in	an	EPS	comprised	matrix.		
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Proportionally	in	biofilms,	the	microorganisms	account	for	less	than	10%	of	the	dry	mass,	whereas	the	matrix	can	account	for	over	90%	[3].		This	conglomeration	of	different	biopolymers	and	water	aids	in	the	cohesion	of	the	cells	of	the	biofilm,	adhesion	to	the	surface	they	are	bound	to,	as	well	as	diffusion	of	various	bacterial	products	[3,8].		Also,	when	the	surrounding	environment’s	nutrients	have	been	depleted,	there	are	enzymes	produced	by	the	bacteria	of	the	biofilm	that	can	break	down	the	biopolymers	of	the	EPS.		This	provides	the	bacteria	with	immediate	access	to	carbon	and	energy	sources	when	needed	[8].		This	mechanism	of	storage	can	sustain	a	biofilm	rather	efficiently	when	considering	the	fact	that	50-90%	of	biofilms	carbon	contents	resides	in	the	EPS	matrix	[1].	The	efficiency	and	resilience	that	biofilms	provide	bacteria	illustrated	thus	far	effectively	shows	how	they	could	be	highly	problematic	in	a	clinical	setting.		In	recent	years,	there	have	been	growing	concerns	about	the	ability	of	biofilms	to	adhere	and	flourish	within	a	patient,	either	on	their	internal	natural	body	surfaces,	such	as	the	mucosal	epithelial	linings	for	many	of	the	body’s	tracts,	or	on	the	abiotic	surfaces	of	indwelling	medical	devices	(IMDs)	[4].		With	their	adapted	resistance	to	many	conventional	antibiotic	treatments,	bacterial	biofilms	are	able	to	survive	the	standard	treatments	that	physicians	traditionally	would	use.		As	such,	these	biofilms	can	eventually	lead	to	clinical	bacteremia	or	even	chronic	infection	[2,4].	With	the	expanding	research	into	the	capability	of	biofilms	to	bind	to	internal	body	surfaces,	we	are	now	able	to	identify	multiple	bacterial	pathologies	that	owe	their	persistence	to	biofilm	formation.		Biofilms	have	been	linked	as	contributive	agents	from	something	as	simple	as	infection	of	a	mild	laceration	to	chronic	
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inflammatory	lung	conditions,	such	as	cystic	fibrosis	[5,7].		Other,	more	benign,	conditions	such	as	urinary	tract	infections	or	middle	ear	infections	can	also	have	biofilms	contributing	to	their	severity	[4].			Due	to	the	numerous	resident	bacteria	within	a	biofilms’	constant	exchange	of	resistance	plasmids,	biofilm	aggregates	have	greater	genetic	diversity	than	standard	planktonic	bacteria.		The	secretion	of	endotoxin	achieved	by	biofilm	bacteria	aid	in	making	them	more	virulent.		Factor	these	facts	in	with	the	reduced	susceptibility	to	the	antimicrobial	agents	that	would	traditionally	eradicate	the	planktonic	form	of	the	same	bacteria,	and	the	treatment	of	these	otherwise	brief	infections	becomes	much	more	difficult	[1,7].		There	has	even	been	evidence	to	support	the	claim	that	clinical	biofilms	can	even	acquire	the	ability	to	evade	their	host’s	own	immune	responses	[1,2].		Thankfully,	these	infections	are	typically	confined	to	a	single	location,	as	the	biofilm	detaching	from	the	surface	it’s	adhered	to	would	usually	threaten	its	own	prosperity	[7].				In	many	ways,	biofilm	infection	of	IMDs	is	very	similar	to	the	situations	as	described	above.		Wherever	the	device	is	located	is	where	the	biofilm	will	form	and	similarly	use	the	surrounding	host	environment	to	proliferate.		Contrarily,	with	biofilm	infection	on	the	abiotic	surface	of	IMDs	within	a	patient,	the	option	of	removal	is	a	perfectly	viable	treatment	plan.		This	will	typically	be	done	in	coupling	with	systemic	antibiotic	therapy	to	ensure	that	any	planktonic	cells	that	detach	when	the	biofilm-infected	device	is	extracted	are	eradicated	before	causing	further	infection	[4].		For	some	IMDs,	such	as	urinary	catheters,	this	treatment	option	is	both	simple	and	effective	seeing	as	how	they	can	be	easily	removed.		However,	there	
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are	IMDs,	like	dialysis	fistulas	or	artificial	heart	valves	that,	if	infected,	can	lead	to	severe	systemic	bacteremia	and	be	extremely	expensive,	not	to	mention	dangerous,	to	replace.		The	best	viable	approach	to	the	treatment	of	biofilm-infected	IMDs	such	as	these	is	a	combination	of	surgical	removal	and	antibiotic	treatment,	just	like	with	simple	IMDs.		However,	these	procedures	can	present	much	higher	risks	to	the	patient	and	expenditures	ranging	from	$15,000	to	$50,000,	depending	on	the	IMD	and	the	invasiveness	of	the	surgical	procedure	required	[2,4].	
Enterobacteriaceae			 Of	the	known	biofilm-producing	bacteria	relevant	in	both	research	and	clinical	settings,	there	are	numerous	members	belonging	to	the	bacterial	family	Enterobacteriaceae.		Taxonomically,	the	bacterial	family	currently	has	53	genera	and,	of	these,	26	are	known	to	be	associated	with	infections	in	humans	[9].		Members	of	this	family	share	numerous	characteristics,	such	as	being	typically	small,	gram	negative,	non-sporing,	straight	rods	that	are	facultatively	anaerobic	and	grow	well	at	standard	human	body	temperature,	37℃	[9].		There	are	several	clinically	significant	members	of	this	bacterial	family	that	are	causing	concern	in	the	medical	field,	as	their	rapid	adaptations	outdo	our	current	treatments.		Between	their	effectiveness	and	virulence	as	pathogens	and	their	rapidly	evolving	tolerance	to	the	most	powerful	weapons	in	our	antibiotic	arsenal,	these	members	of	the	Enterobacteriaceae	family	have	researchers	scrambling	for	a	leg	up.		 One	such	genus	of	concern	is	Klebsiella.		All	Klebsiella	species	tend	to	act	as	opportunistic	pathogens,	typically	only	infecting	individuals	who	are	immunocompromised	or	suffering	for	another	chronic	illness.		They	are	an	
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incredibly	adaptive	class	of	bacteria,	being	able	to	survive	in	both	the	environment	(water	sources,	soil,	sewage,	etc.)	as	well	as	the	mucosal	surfaces	of	mammals,	including	humans.		As	such,	the	clinical	areas	of	most	concern	for	Klebsiella	infection	are	ones	such	as	the	urinary,	respiratory,	or	intestinal	tracts.		This	genus’	most	medically	famous	species,	Klebsiella	pneumonieae	(KP),	is	the	most	common	cause	of	community-acquired	bacterial	pneumonia,	particularly	among	chronic	alcoholics.		When	put	into	perspective	of	bacterial	species	causing	gram-negative	bacteremia,	
Klebsiella	species	are	second	only	to	the	infamous	Escherichia	coli.	This	genus	has	begun	to	exhibit	multiple	species	strains	that	are	increasingly	antibiotic-resistant	to	many	conventional	antibiotics	due	to	their	production	of	extended-spectrum	𝛽-lactamases	that	cleave	the	𝛽-lactam	structure	of	said	antibiotics	[10].		 Another	tenacious	genus	within	the	Enterobacteriaceae	family	that	has	caused	serious	infection	in	neonates	and	immunocompromised	individuals	is	
Citrobacter.		This	genus	raises	particular	concerns	due	to	its	member’s	ability	to	cause	infections	affecting	a	patient’s	Central	Nervous	System	(CNS)	more	severely	than	simply	causing	bacteremia	or	sepsis	as	other	genera	do.		These	bacteria	are	typically	located	in	the	feces	of	mammals	and	can	then	spread	through	water,	soil,	and	even	food	[9,11].		If	infected	with	a	virulent	Citrobacter	strain,	an	individual	could	develop	bacterial	meningitis.		In	80%	of	these	confirmed	cases	the	disease	can	eventually	lead	to	painful	and	debilitating	CNS	abscesses.		Signs	and	symptoms	of	
Citrobacter	meningitis	or	sepsis	include	temperature	instability,	irritability,	decreased	oral	intake,	jaundice,	vomiting,	lethargy,	hypotonia,	and	possibly	seizures	[11].		A	particular	species	that	contributes	to	these	clinical	manifestations	is	
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Citrobacter	freundii	(CF),	which	is	virtually	always	resistant	to	standard	bacterial	antibiotics	like	ampicillin	or	cephalosporins,	making	it	very	difficult	to	treat.		It	usually	takes	a	varied	combination	of	antibiotics	tailored	to	a	specific	situation	coupled	with	surgical	draining	of	CNS	abscesses	to	effectively	treat	such	illness	presented	by	this	species	of	Citrobacter.			Even	with	these	combinations	of	drugs	and	surgery,	some	physicians	have	referred	to	the	overall	effectiveness	of	this	treatment	as	“generally	disappointing.”	[11]		 Another	genus	of	Enterobacteriacae	deemed	highly	important	in	the	realm	of	causing	serious	nosocomial,	opportunistic	infections	is	Enterobacter.		These	bacteria	are	a	common	species	that	have	been	linked	to	serious	cases	of	bacteremia,	endocarditis,	osteomyelitis,	and	multiple	other	chronic	diseases.		An	exemplary	species	of	the	whole	genus,	demonstrating	their	resilience	and	pathogenicity,	is	
Enterobacter	cloacae	(ECL).		The	species	normally	resides	as	commensal	microflora	in	the	intestinal	tracts	of	humans	and	other	animals.		As	a	pathogen,	it	is	able	to	create	biofilms,	secrete	cytotoxins,	and	exhibit	multi-drug-resistance.		This	species	is	intrinsically	resistant	to	ampicillin,	amoxicillin,	first-generation	cephalosporins,	as	well	as	cefoxitin.		This	remarkable	resistance	is	owed	to	the	bacteria’s	production	of	constitutive	Amp	C	β-lactamase.		However,	in	recent	years,	clinical	isolates	have	been	found	that	have	the	ability	to	produce	carbapenemase,	which	can	render	one	of	our	most	powerful	antimicrobial	drugs	useless	in	treating	an	infection	[12].			 As	stated	earlier,	all	of	these	genera	mentioned	exhibit	powerful	antibiotic	resistance	that	makes	treatment	of	associated	infections	highly	complicated.		The	most	concerning	development	in	recent	years,	as	mentioned	briefly	with	ECL,	is	that	
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some	genera	of	Enterobacteriaceae	have	developed	adaptations	against	our	“antibiotic	of	last	resort”:	Carbapenems	[12].		Every	genus	mentioned	above,	not	just	
Enterobacter,	includes	certain	species	that	can	produce	strains	exhibiting	this	new	adaptation	of	defense.		These	species	make	up	the	classification	of	Carbapenem	Resistant	Enterobacteriaceae	(CRE).		When	the	first	beta	lactamases	were	developed	by	bacteria	to	combat	penicillin	in	the	1960s,	carbapenems	were	created	as	humanity’s	counter	[13].		It	is	a	member	of	the	antimicrobial	class	of	𝛽-lactams	and	possesses	the	broadest	spectrum	of	efficacy	against	both	gram-positive	and	gram-negative	bacteria	[13].		Carbapenems	attack	bacteria	by	entering	through	their	outer	membrane	proteins	and	inhibiting	the	enzymes	within	the	cell	responsible	for	peptidoglycan	production	via	penicillin	binding	proteins	(PBPs).		This	ultimately	results	in	the	weakening	and	eventual	lysis	of	the	cell’s	protective	structure,	leading	to	cell	death	[13].		Carbapenemases	are	𝛽-lactamases	that	CRE	can	produce	specifically	to	attack	the	structure	of	the	antibiotic	before	it	ever	reaches	the	PBPs,	rendering	it	useless.		There	are	also	other	methods,	such	as	efflux	pumps	and	gene	mutations	that	some	bacteria	can	utilize	to	also	prevent	carbapenems	from	performing	their	function	[13].		The	best	treatments	we	have	for	bacterial	infections	exhibiting	such	resistance	are	combination	antibiotics,	monotherapies,	or	returning	to	previously-thought	obsolete	drugs,	such	as	colistin.		At	this	point,	there	is	no	single	treatment	option	that	is	superiorly	effective	against	CRE	[14].	
Secondary	Metabolites		 It	has	been	mentioned	previously	that	bacteria	have	multiple	mechanisms	for	interacting	with	one	another.		These	interactions	can	be	either	cooperative	or	
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hostile	depending	on	the	situations	and	the	interactive	tendencies	of	the	particular	bacteria	involved.		What	was	not	directly	mentioned,	however,	were	the	actual	agents	responsible	for	these	interactions.		The	integral	agents	of	the	microbial	community	responsible	for	these	cell-to-cell	interactions	can	simply	be	referred	to	as	secondary	metabolites	(SMs).		 SMs	can	be	defined	as	cellular	products	that	do	not	play	an	essential	role	in	growth,	development,	or	reproduction	of	the	producing	organism.		These	metabolites	are	often	bioactive	compounds	and	can	perform	important	functions	in	bacterial	defense,	competition,	signaling,	and	ecological	interactions	[15].		These	products	are	not	found	among	bacteria	that	are	still	in	their	primary	growth	phase	(trophophase),	but	are	produced	when	bacteria	enter	their	subsequent	production	phase	(idiophase)	[16].		SM	production	is	typically	brought	on	due	to	a	depletion	or	exhaustion	of	an	essential	nutrient	(such	as	Carbon),	the	presence	of	some	other	inducer,	or	simply	a	decrease	in	growth	rate	[16,17].		The	secondary	metabolites	are	typically	produced	by	modifying	primary	metabolite	synthases	that	ultimately	result	in	primarily	amino	acid	derivatives	that	can	be	used	for	a	wide	variety	of	functions	[16,18].		Antibiotics,	toxins,	pheromones,	and	even	the	auto-inducers	mentioned	above	in	relation	to	quorum	sensing	are	all	examples	of	SMs	[17].		 Clinically,	the	ability	of	SMs	to	have	antibiotic	properties	is	the	most	significant	as	far	as	humans	are	concerned.		Infection-preventing	antibiotics	such	as	bacitracin	or	erythromycin	are	both	derived	from	SMs	made	by	some	bacteria	with	the	original	purpose	to	be	used	against	other	bacteria	[18].		This	method	of	using	bacteria’s	own	weapons	against	them	has	been	the	foundation	of	modern	bacterial	
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infection	treatment	since	Fleming’s	ingenuity	resulting	in	penicillin.		Ultimately,	this	foundation	is	all	possible	due	to	bacteria’s	own	adaptations	for	self-preservation	against	other	microbes.		The	antimicrobial	SMs	produced	can	react	to	other	bacteria	by	inhibiting	their	growth,	which	in	turn	allows	the	bacteria	secreting	them	more	nutrients	in	their	environment.		Another	possibility,	for	some,	is	simply	killing	rival	bacteria	outright	to	achieve	the	same	effect	[19,20].		These	two	methods	of	microbial	warfare	are,	as	such,	classified	as	bacteriostatic	(inhibiting)	or	bactericidal	(killing)	actions	[19].			 The	current	experiment	utilizes	all	of	the	above	information	in	an	effort	to	determine	the	effect	and	efficacy	of	a	currently	unknown	product	secreted	by	KP.		We	believe	it	is	likely	a	SM	considering	its	characteristics	of	what	appears	to	be	competitive	inhibition	on	CF	and	ECL	biofilm	formation.	Both	of	these	bacterial	species	have	exhibited	multiple	drug	resistance	(MDR)	to	traditional	treatments,	and	as	such,	new	methods	of	treatment	are	in	demand.		This	product	has	been	found	to	be	present	in	the	filtered,	cell-free	spent	media	from	a	KP	broth	culture	and	appears	to	produce	similar	effects	in	inhibiting	these	species	in	this	form	as	it	is	directly	secreted	from	living	cells.		Both	stages	of	biofilm	attachment	and	maturation	for	the	two	species	in	question	are	analyzed	when	introduced	to	the	filtered	KP	liquid	containing	the	unknown	product.		Multiple	assays	were	performed	in	order	to	determine	optical	density,	mass,	and	cell	viability	of	the	biofilms	produced.		Hopefully,	with	the	data	and	scientific	deduction	from	these	trials,	a	new	method	of	
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treating	biofilms	produced	by	the	growing	threat	of	MDR	Enterobacteriaceae	may	emerge.		
Materials	and	Methods	
Strains	and	Media		 Klebsiella	pneumoniae	(ATCC#13883),	Citrobacter	freundii	(ATCC#8090),	and	
Enterobacter	cloacae	(ATCC#23355)	stocks	were	purchased	from	the	American	Type	Culture	Collection.		Luria	broth	(LB),	both	as	a	broth	and	an	agar	medium,	was	used	to	propagate	bacterial	strains.		When	necessary,	Carbenicillin	(10	𝜇𝑔/mL)	was	added	to	media	for	the	selection	of	K.	pneumoniae.	
Preparation	of	Cell-Free	Spent	Media		 Fresh	overnight	cultures	of	KP	were	used	to	acquire	the	inhibitory	molecule	of	interest.		Briefly,	5	mL	overnight	cultures	were	pelleted	by	centrifugation	and	the	resulting	supernatant	was	further	purified	via	a	0.22-micron	syringe	filter.		The	filtered	supernatant	was	then	combined	in	equal	portions	with	the	LB	broth	and	immediately	used	for	biofilm	assays.	
Zones	of	Inhibition		 To	determine	an	average	zone	of	inhibition	(ZOI)	for	the	unknown	secreted	molecule	from	KP,	overnight	cultures	of	bacteria	(LB	broth,	37℃)	of	CF	and	ECL	were	used	to	create	bacterial	lawns	on	LB	agar	plates.	15 𝜇𝐿	of	overnight	KP	culture,	KP	cell-free	supernatant,	or	varying	concentrations	of	Ampicillin	were	spotted	onto	
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the	lawns.	Plates	were	incubated	at	37℃	for	24	hours	and	zones	of	inhibition	(millimeters)	were	measured.			
Biofilm	Formation		 In	order	to	produce	biofilms	for	the	experiment,	overnight	cultures	of	CF	and	ECL	were	adjusted	to	an	𝑂𝐷!""	reading	of	0.01	(~1	x	10!	cells/mL)	in	LB	broth	and	seeded	into	a	96	well	microtiter	plate.		For	experiments	involving	the	attachment	phase,	CF	and	ECL	were	seeded	either	into	wells	with	LB	broth	or	a	combination	of	equal	parts	LB	and	KP	cell-free	spent	media.		LB	(no	bacteria)	only	wells	served	as	a	control	for	background.		The	96	well	plates	were	then	covered	with	parafilm	and	incubated	at	37℃	for	24h.		For	experiments	involving	the	maturation	phase,	CF	and	ECL	were	seeded	(~1x106cells/mL)	into	the	wells	with	half	the	amount	of	LB	broth	and	incubated	for	4h	at	37℃.	After	this	short	incubation	to	establish	bacterial	biofilms,	fresh	LB	or	KP	cell	free	spent	media	was	added	accordingly	to	control	and	experimental	wells.		The	96	well	plates	were	covered	with	parafilm,	and	incubated	an	additional	24h	at	37℃.	
Assessing	Biofilm	Cell	Density,	Biofilm	Mass,	and	Bacterial	Metabolism		 Biofilm	characteristics	were	assessed	by	UV/VIS	spectral	readings	using	a	GENESYS	10S	or	Thermo	Fisher	Multiskan	microtiter	plate	spectrophotometer.	Each	biofilm	assay	was	done	in	triplicate	with	each	of	the	three	trials	having	multiple	replicated	independent	samples.	
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Biofilm	Cell	Density	Assay		 After	incubation,	bacterial	biofilms	were	dislodged	from	wells	and	optical	density	(𝑂𝐷!"")	was	determined.	A	well	containing	LB	broth	only	was	used	as	a	blank.			
Biofilm	Mass	Assay		 The	dye	crystal	violet	(CV)	was	used	to	assess	biofilm	mass.	Briefly,	the	liquid	portion	of	the	biofilm	was	removed	from	each	well	and	wells	were	washed	once	with	1X	PBS.	A	0.1%	CV	solution	was	added	and	incubated	at	room	temperature	for	ten	minutes.	The	dye	was	then	pipetted	off	and	wells	were	again	washed	with	1X	PBS	and	the	remaining	dye	within	the	biofilm	cells	was	released	using	33%	acetic	acid.	Spectrophotometer	readings	(OD595)	were	used	to	assess	the	amount	of	released	dye.	
Biofilm	Cell	Metabolism	Assay		 For	determining	cell	viability,	this	experiment	incorporated	the	use	of	an	MTT	assay.	Briefly,	the	yellow	colored	MTT	is	reduced	to	its	insoluble	formazan,	yielding	a	purple	color	if	the	cells	were	actively	metabolizing.		To	do	this,	MTT	(5mg/mL)	was	added	to	the	96-well	plate	and	incubated	at	37℃	for	thirty	minutes.	Acidic	isopropanol	was	added	to	resolubilize	excess	MTT.	Spectrophotometer	readings	(𝑂𝐷!"#)	were	used	to	assess	the	amount	of	reduced	MTT.	
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Biofilm	Viability		 Standard	plating	and	dilution	methods	were	used	to	determine	colony-forming	units	(CFU)	of	the	biofilms.	Wells	were	serially	diluted	and	plated	on	LB	agar	plates,	incubated	at	37℃	for	24h,	and	enumerated	the	next	day.	
Results	and	Discussion	
Inhibition	of	CF	and	ECL	Biofilm	Attachment	Preliminary	studies	investigating	the	KP	molecule’s	effect	on	planktonic	culture	has	shown	definitive	inhibition	of	CF	and	ECL	growth	in	culture.	Taking	this	information	into	consideration	we	first	tested	the	ability	of	this	molecule	to	inhibit	the	beginning	stages	of	biofilm	development,	the	attachment	stage.	Early	biofilm	attachment	was	assessed	for	cell	density	(optical	density),	biofilm	mass	(crystal	violet	staining),	and	biofilm	cell	viability	(MTT	and	CFU	enumeration).	The	96	well	microtiter	plates	were	uniformly	inoculated	with	the	same	amount	of	CF	or	ECL	(~1x106	cells/mL)	with	LB	alone	or	equal	amounts	of	LB	and	KP	cell	free	spent	media.	Each	of	the	plates	could	then	be	assessed	for	the	four	different	assays	at	once	(Figure	1A).			
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	 Controls	for	each	assay	consisted	of	LB	only	wells	containing	no	bacteria.	There	was	a	visible	decrease	in	turbidity	between	the	control	and	experimental	wells.		Optical	density	readings	were	consistent	over	the	three	independent	trials	and	showed	a	62%	decrease	for	CF	biofilms	treated	with	the	KP	molecule	and	a	68%	decrease	in	ECL-treated	biofilms	(Figure	2A/2B).	However,	thanks	to	our	additional	row	of	wells	containing	nothing	but	LB	broth,	we	were	able	to	determine	that	there	was	bacterial	biofilm	development	in	all	wells.		This	indicates	that,	at	the	point	of	biofilm	attachment,	the	uncharacterized	product	from	KP	is	inhibitory	to	attachment	and	eventual	production	but	is	unable	to	fully	prevent	attachment	of	
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bacteria.		It	is	important	to	note	that	we	have	thus	far	not	been	able	to	isolate	and	purify	the	molecule	of	interest	and	so	the	cell	free	spent	media	contains	very	dilute	amounts	of	the	molecule.	It	is	possible	that	upon	isolation	and	purification	of	the	molecule	that	a	completely	inhibitory	effect,	in	regards	to	attachment,	could	be	possible.		Figure	1A	shows	the	microtiter	assay	plate	at	the	conclusion	of	all	performed	assays.		Dilution	plates	for	CF	(Figure	1B)	and	ECL	(Figure	1C)	were	also	compared	to	further	illustrate	the	inhibition	of	both	bacteria.	
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	For	assessment	of	biofilm	mass,	CV	was	used	to	stain	attached	cells	on	the	96	well	plates.	Cells	that	take	up	the	CV	stain	are	lysed,	releasing	the	dye,	and	mass	can	be	calculated	as	a	proportion	by	absorbance	at	OD595.	When	CF	was	treated	with	the	KP	molecule	there	was	a	73%	reduction	in	biofilm	mass	in	comparison	to	the	CF	untreated	control	(Figure	3A/3B).	The	KP	molecule	appears	to	have	had	an	even	more	prominent	reduction	of	85%	on	ECL	biofilm	mass	during	attachment	phases	(Figure	3A/3B).		We	believe	this	to	be	indicative	of	a	major	reduction	in	biofilm	mass	due	to	the	inhibitory	actions	of	the	uncharacterized	molecule.	
1B	 1C		
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	 The	OD	and	CV	assays	only	express	cells	in	terms	of	amount	of	cells,	but	are	unable	to	indicate	whether	those	cells	are,	in	fact,	alive	or	dead.	To	determine	if	there	was	a	reduction	in	cell	viability	we	implemented	an	MTT	assay.		In	this	assay	the	yellow	MTT	is	reduced	to	a	purple	formazan	product	by	actively	metabolizing	bacterial	cells.	Thus,	the	amount	of	reduced	product	can	be	determined	by	spectrophotometer	readings	(OD570)	and	the	proportion	of	cells	that	are	viable	can	be	calculated.		There	was	a	reduction	in	both	CF	and	ECL	cell	viability,	though	this	reduction	was	not	as	drastic,	as	compared	to	the	other	OD	and	CV	reductions.		CF	exhibited	a	52%	reduction	in	viable	cells	between	control	and	experimental	wells	while	ECL	revealed	a	substantially	greater	71%	reduction	between	its	two	conditions	(Figure	4A/4B).		As	such,	for	both	CF	and	ECL	at	the	attachment	stage	of	
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biofilm	formation,	there	is	a	quantifiable	decrease	in	viable	cells	present	in	the	cultures.			
Inhibition	of	CF	and	ECL	Biofilm	Maturation			 We	then	tested	the	ability	of	this	molecule	to	inhibit	early-stages	of	maturation,	when	the	biofilms	are	forming,	but	not	fully	mature	yet.	Similarly	to	attachment,	biofilm	maturation	was	assessed	for	cell	density	(optical	density),	biofilm	mass	(crystal	violet	staining),	and	biofilm	cell	viability	(MTT	and	CFU	enumeration).	The	96	well	microtiter	plates	were	uniformly	inoculated	with	the	same	amount	of	CF	or	ECL	(~1x106	cells/mL)	and	half	the	amount	in	each	well	of	LB	alone	(100	𝜇𝐿).		This	plate	was	placed	in	the	37℃	incubator	for	a	total	of	4	hours.		After	this	span	of	time,	the	remaining	amounts	of	LB	broth	or	KP	product	were	added	to	their	respective	wells.	Each	of	the	plates	were	assessed	for	the	four	different	assays	at	once,	shown	in	Figure	5A.		Controls	for	each	assay	were	comprised	of	wells	filled	with	only	LB	and	no	bacteria.	There	was	a	visible	decrease	in	turbidity	between	the	control	and	experimental	wells.		Optical	density	readings	were	consistent	over	the	three	independent	trials	and	showed	a	56%	decrease	for	CF	biofilms	treated	with	the	KP	molecule	and	a	65%	decrease	in	ECL	treated	biofilms	(Figure	6A/6B).		Both	of	these	values	were	only	slightly	(<~7%)	less	than	what	we	found	for	the	attachment	series,	indicating	a	slight	lessening	in	effectiveness	of	the	molecule	at	inhibiting	biofilm	formation	at	the	maturation	stage.	
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Due	to	this	experimental	series	focusing	on	the	biofilm	phase	of	maturation,	it	was	expected	that	we	would	see	biofilm	growth	in	all	wells	except	our	LB	only	wells.		This	fact	reinforces	that,	at	the	dilutions	used	for	this	experiment,	the	KP	product	in	question	possesses	bacteriostatic	rather	than	bactericidal	effects	due	to	pre-formed	biofilms	still	being	present,	yet	inhibited	from	the	point	of	KP	product	addition	onward.		Figure	5A	shows	the	microtiter	assay	plate	at	the	conclusion	of	all	performed	assays.		Dilution	plates	for	CF	(Figure	5B)	and	ECL	(Figure	5C)	were	also	compared	to	further	illustrate	the	inhibition	of	both	bacteria.	
	
25	
	 	The	same	method	of	using	CV	to	stain	attached	cells	on	the	96	well	plates	that	was	used	for	the	attachment	phase	was	used	in	the	maturation	trials.	The	mass	can	be	calculated	as	a	proportion	by	absorbance	at	OD595,	as	before.	For	this	series,	when	CF	was	treated	with	the	KP	molecule	there	was	a	89%	reduction	in	biofilm	mass	in	comparison	to	the	CF	untreated	control,	demonstrating	what	appears	to	be	superior	action	of	the	KP	molecule	when	compared	with	the	attachment	data	(Figure	7A/7B).	Contrarily,	ECL	only	exhibited	an	average	reduction	of	71%	in	biofilm	mass	when	added	4	hours	after	incubation	began,	which	is	>10%	less	effective	than	when	the	filtrate	was	introduced	immediately	(Figure	7A/7B).	
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	To	determine	if	the	cells	present	were	alive	or	dead,	an	MTT	assay	was	utilized.		The	amount	of	reduced	product	was	determined	by	spectrophotometer	readings	(OD570)	and	the	proportion	of	cells	that	are	viable	was	then	calculated.		61%	average	viable	cell	reduction	was	found	between	the	control	and	experimental	categories	for	CF,	which	is	~8%	greater	efficacy	than	when	the	KP	molecule	was	added	to	inhibit	the	attachment	phase	of	biofilm	formation	(Figure	8A/8B).		Inversely,	the	ECL	averages	indicated	a	60%	reduction	of	viable	cells	due	to	the	filtrate’s	addition	at	the	maturation	stage	which	is	>10%	less	efficacy	than	when	it	was	added	for	attachment	(Figure	8A/8B).		For	both	CF	and	ECL	at	the	maturation	
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stage	of	biofilm	formation,	we	can	conclude	that	there	is	a	similar	quantifiable	decrease	in	viable	cells	present	in	the	cultures	read	by	the	spectrophotometer	(𝑂𝐷!"#)	as	compared	to	the	attachment	stage	trails.			
	 	
Determination	of	KP	molecule	Zones	of	Inhibition	(ZOI)	 	Lastly,	it	was	determined	from	the	data	that	the	unknown	molecule	secreted	from	KP	has	the	capability	to	create	a	ZOI	that	closely	resembles	the	same	action	enacted	by	lower	concentrations	of	the	antibiotic	Ampicillin	on	lawns	of	CF	and	ECL.			In	too	low	dilutions,	the	antibiotic	won’t	create	any	ZOI	of	CF	lawns	(Figure	9A/9B).		
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However,	the	filtrate	is	capable	of	creating	a	ZOI	very	similar	to	what	would	be	produced	if	the	KP	cells	were	placed	on	the	lawn.		With	ECL,	which	appears	to	be	more	susceptible	to	Ampicillin	than	CF,	the	KP	filtrate	proved	to	be	slightly	less	effective	than	the	lowest	antibiotic	dilution	we	tested,	but	more	effective	than	the	KP	cell	trial.	
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Conclusions	
	 The	results	of	this	study	are	indicative	of	the	uncharacterized	KP	molecule	possessing	inhibitory	effects	on	CF	and	ECL	biofilm	formation	at	both	stages	of	attachment	and	maturation	at	the	dilutions	used.		For	each	condition	tested,	there	was	substantial	reduction	by	more	than	50%	between	control	groups	and	those	exposed	to	the	uncharacterized	product.		This	shows	that	the	molecule	in	question	has	inhibitory	effects	on	the	bacteria’s	biofilm	cell	density,	mass,	and	cell	viability,	ultimately	weakening	these	bacteria’s	biofilms.		 The	mechanism	of	how	exactly	this	molecule	does	this,	as	well	as	what	exactly	this	product	from	KP	is	categorized	as,	is	still	in	question.		We	are	not	certain	if	this	product	exhibits	strictly	bacteriostatic	effects	or	if	there	is	possibility	for	more	dramatic,	bactericidal	action	upon	purification.		Again,	only	the	liquid,	dilute	form	of	this	product	was	used	for	this	study,	and	the	behavior	of	the	KP	product	in	higher	concentrations	with	higher	concentrations	of	bacteria	remains	to	be	tested.				 The	future	goals	of	this	series	of	experiments	would	include	the	isolation,	identification,	and	successful	purification	of	this	unknown	product	secreted	by	KP	so	that	the	full	extent	of	its	antimicrobial	effects	could	then	be	analyzed.		At	present,	the	results	of	this	study	are	highly	optimistic	for	multiple	practical	applications	of	the	product	in	question.		There	is	the	possibility	of	alternative	solutions	to	CF	and	ECL	infections	rather	than	traditional,	high-dose	antibiotics.		Should	an	infection	develop	biofilms	and	run	the	risk	of	becoming	a	chronic	illness	in	a	patient,	we	now	have	an	antimicrobial	agent	that	may	be	capable	of	treating	MDR	CF	and	ECL,	giving	medicine	a	new	weapon	in	microbial	warfare.	
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